Plasmalyte

Phase 1Small molecule

SSeoul National University Hospital

Plasmalyte is one of 81 small molecule programs targeting Brain Edema. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain EdemaActive, not recruiting

Coronary Artery BypassActive, not recruiting

HypotensionActive, not recruiting

ScoliosisActive, not recruiting

Brain EdemaPhase 1

Active, not recruiting

Coronary Artery BypassPreclinical

Active, not recruiting

HypotensionPreclinical

Active, not recruiting

ScoliosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

148 competitors in Coronary Artery Bypass

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Phase 3

1 2

Bactroban

PPadagis LLC

Phase 3

1 3

Aggrastat

MMedicure

Phase 3

1 4

Arixtra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 5

Intralipid

AstraZeneca

Phase 3

1 6

Low-Dose Aspirin

PPharmaEssentia Japan K.K.

Phase 3

1 7

Acadesine

Merck & Co.

Phase 3

1 8

Glulisine

EEmory University

Phase 3

1 9

CGT003 (E2F Duplex Decoy)

AAnesiva, Inc.

Phase 3

1 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Fluid Therapy2 trials

Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery

Completed·—·Phase 4·NCT02312999·160 enrolled

Perioperative Fluid Therapy With Balanced Crystalloids

Completed·UUniversity Hospital Olomouc·Phase 3·NCT02691676·112 enrolled

Terminated·UUniversity of British Columbia·N/A·NCT02463175·14 enrolled

Coronary Artery Bypass1 trial

Effects of Colloid and Crystalloid on the Microcirculatory Alterations During Off-pump Coronary Artery Bypass Surgery

Completed·SSeoul National University Hospital·N/A·NCT01713166·120 enrolled

4 more indications

Hypotension1 trial

Efficacy of 5% Albumin v/s Plasmalyte in Combination With 20% Albumin for Fluid Resuscitation in Cirrhosis With Sepsis Induced Hypotension

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06076330·120 enrolled

Fluid Resuscitation1 trial

Fluid Resuscitation in Burn Patients

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03118362·28 enrolled

Brain Edema1 trial

A Low ChloridE hyperTonic Solution for Brain Edema

Completed·EEmory University·Phase 1·NCT03204955·59 enrolled

Children1 trial

Comparison of Ringer Lactate and Isotonic Acetate Solution as Perioperative Maintenance Fluid for Children

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT02936167·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Plasmalyte. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plasmalyte compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plasmalyte. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSeoul National University Hospital

Plasmalyte

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Fluid Therapy2 trials

Infection1 trial

Cardiac Surgery1 trial

Scoliosis1 trial

Coronary Artery Bypass1 trial

Hypotension1 trial

Fluid Resuscitation1 trial

Brain Edema1 trial

Children1 trial

References

Drug Info

Quick Facts

Related News